Background
Rapidly initiating antiretroviral therapy (ART) and achieving viral suppression (VS) among newly diagnosed people with HIV (PWH) are cornerstones of HIV care. COVID-19 caused far-reaching disruptions in health services, including for HIV treatment and laboratory monitoring. We characterized trends in early ART (eART) and early VS (eVS) among PWH before (2018-2019) vs. during (2020-2021) the COVID-19 pandemic to assess potential impacts of these disruptions.
Methods
We included treatment-naïve adult (≥18 years old) PWH at entry into care in one of 13 cohorts in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) from 2018–2021. We examined subgroup differences in the proportion achieving eART (ART initiation ≤30 days after entry) and eVS (HIV-1 viral load [VL] <200 copies/mL, ≤180 days after ART initiation). We followed PWH until ART initiation, VS, cohort close date, study end (12/31/2021), or death; due to the short observation period, we assumed no loss to follow-up. We examined factors associated with timing of ART and VS using multivariable Cox models, including age, enrollment year, race/ethnicity, sex, HIV risk group, CD4 count, VL, diagnosed alcohol or substance use disorders, and mental illness diagnoses at entry.
Results
Among 2784 PWH included, 79.8% (n=2223) achieved eART. Compared with 2018 (81.4%, n=874/1074), a higher proportion of PWH entering care in 2019 achieved eART (86.1%, n=794/922); this progress slowed significantly in 2020 (60.8%; n=315/518), then rebounded in 2021 (88.9%; n=240/270; p=0.001). Multivariable analysis showed that PWH in the Northeast had shorter time to ART initiation compared to those in the South (HR=1.27, CI: 1.07-1.52). PWH ≥60 years old had longer time to ART (HR=0.80, CI: 0.67-0.95) than younger PWH. Overall, 91% (n=1778/1953) achieved eVS. Compared with 2018 (89.0%), a higher proportion of PWH entering care in 2019 (92.6%) achieved eVS, with slowing progress in 2020 (87.3%) that improved in 2021 (97.4%; p<0.01). PWH with CD4 <200 cells/mm3 at entry had slower time to VS than those with higher CD4 counts (all p <0.05).
Conclusions
Progress towards ending the HIV epidemic in the US slowed during the first year of the COVID-19 pandemic with lower rates of eART and eVS. Both recovered by 2021, yet persistent gaps remain for PWH in the South, older adults, and those with advanced HIV, who should be prioritized for earlier diagnosis, and engagement in care and treatment.